BIOTECH MA

Advertisement
Jan 07 2026BUSINESS

Big Pharma's Urgent Quest for New Drugs

Big Pharma companies are in a rush to buy biotech firms. Why? They face a huge problem. Many of their top-selling drugs will soon lose patent protection. This is called the "patent cliff. " By 2032, they could lose over $170 billion in sales. To avoid this, they need new drugs fast. That's where bi

reading time less than a minute